Showing results (11-20 of 40) with videos related to
Sort By:
Pageof 4
Journal of Medical Genetics|August 30, 2017
Genetic Severity Score predicts clinical phenotype in NF2Dorothy Halliday, Beatrice Emmanouil, Pieter Pretorius, et al.Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|July 8, 2022
A Case for Genetic Testing in Isolated Tympanic ParagangliomasManu K Shrivastava, John F Curran, Fintan Sheerin, et al.The Laryngoscope|November 21, 2018
Progression of hearing loss in neurofibromatosis type 2 according to genetic severityBeatrice Emmanouil, Rory Houston, Anne May, et al.Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|March 26, 2026
Inner Ear Schwannomas as a Risk Factor for Early Hearing Loss Independent of Vestibular Schwannoma Growth in NF2-related SchwannomatosisMarina Brimioulle, Pieter Pretorius, Nathaniel McHugh, et al.Human Molecular Genetics|August 14, 2003
Allelic variation in normal human FBN1 expression in a family with Marfan syndrome: a potential modifier of phenotype?Sarah Hutchinson, Andre Furger, Dorothy Halliday, et al.Clinical Genetics|April 18, 2019
Trends in phenotype in the English paediatric neurofibromatosis type 2 cohort stratified by genetic severityDorothy Halliday, Beatrice Emmanouil, Grace Vassallo, et al.Journal of Neurology|March 13, 2014
Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2Rosalie E Ferner, Adam Shaw, D Gareth Evans, et al.Neuro-Oncology Practice|April 26, 2018
Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluationKatrina A Morris, John F Golding, Patrick R Axon, et al.Genes|September 28, 2021
Investigation and Management of Apparently Sporadic Central Nervous System Haemangioblastoma for Evidence of Von Hippel-Lindau DiseaseHugh Furness, Louay Salfity, Johanna Devereux, et al.Journal of Neuro-Oncology|November 1, 2016
Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohortKatrina A Morris, John F Golding, Claire Blesing, et al.Pageof 4